HomeCompareBLUE vs SBUX

BLUE vs SBUX: Dividend Comparison 2026

BLUE yields 40.24% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BLUE wins by $67.9K in total portfolio value
10 years
BLUE
BLUE
● Live price
40.24%
Share price
$4.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$234.9K
Annual income
$39,898.44
Full BLUE calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — BLUE vs SBUX

📍 BLUE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBLUESBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BLUE + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BLUE pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BLUE
Annual income on $10K today (after 15% tax)
$3,420.52/yr
After 10yr DRIP, annual income (after tax)
$33,913.67/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $26,552.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BLUE + SBUX for your $10,000?

BLUE: 50%SBUX: 50%
100% SBUX50/50100% BLUE
Portfolio after 10yr
$201.0K
Annual income
$55,517.45/yr
Blended yield
27.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

BLUE
Analyst Ratings
14
Buy
19
Hold
4
Sell
Consensus: Hold
Price Target
$13.69
+175.5% upside vs current
Range: $5.00 — $25.00
Altman Z
-23.5
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BLUE buys
0
SBUX buys
0
No recent congressional trades found for BLUE or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBLUESBUX
Forward yield40.24%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$234.9K$167.0K
Annual income after 10y$39,898.44$71,136.45
Total dividends collected$177.1K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy
Analyst price target$13.69$104.00

Year-by-year: BLUE vs SBUX ($10,000, DRIP)

YearBLUE PortfolioBLUE Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$14,724$4,024.14$11,121$420.68+$3.6KBLUE
2$21,292$5,537.58$12,548$648.40+$8.7KBLUE
3$30,267$7,483.95$14,440$1,013.98+$15.8KBLUE
4$42,328$9,942.36$17,068$1,617.30+$25.3KBLUE
5$58,285$12,994.66$20,912$2,649.52+$37.4KBLUE
6$79,088$16,723.03$26,875$4,499.29+$52.2KBLUE
7$105,832$21,207.24$36,771$8,014.12+$69.1KBLUE
8$139,762$26,521.85$54,542$15,197.11+$85.2KBLUE
9$182,279$32,733.51$89,602$31,242.49+$92.7KBLUE
10$234,937$39,898.44$167,011$71,136.45+$67.9KBLUE

BLUE vs SBUX: Complete Analysis 2026

BLUEStock

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Full BLUE Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this BLUE vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BLUE vs SCHDBLUE vs JEPIBLUE vs OBLUE vs KOBLUE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.